IGF-I and visfatin levels in retinopathy of prematurity

Journal of Pediatric Ophthalmology and Strabismus

Volumn 49, Issue 2, 2012, Pages 120-124

  Cekmez, Ferhat ^a   Canpolat, Fuat Emre ^a   Çetinkaya, Merih ^a   Pirgon, Ozgur ^b   Aydinoz, Secil ^b   Ceylan, O Melih ^b   Ipcioglu, O Metin ^b   Sarici, Serdar Umit ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SOMATOMEDIN C;

ARTICLE; BIRTH WEIGHT; FETUS; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; INFANT; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; NEWBORN SCREENING; OPHTHALMOSCOPY; PREMATURITY; RETROLENTAL FIBROPLASIA; UMBILICAL CORD BLOOD;

BIOLOGICAL MARKERS; CYTOKINES; FEMALE; FETAL BLOOD; GESTATIONAL AGE; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LUMINESCENT MEASUREMENTS; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RADIOIMMUNOASSAY; RETINOPATHY OF PREMATURITY;

EID: 84862532921     PISSN: 01913913     EISSN: None     Source Type: Journal    
DOI: 10.3928/01913913-20110531-01     Document Type: Article

References (30)

1. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. Am J Ophthalmol. 1942;25:203-204.
2. Gilbert C, Fielder A, Gordillo L, et al. International NO-ROP Group. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics. 2005;115:e518-e525.
3. Hellström A, Hård AL, Engström E, et al. Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics. 2009;123:e638-e645.
4. Löfqvist C, Andersson E, Sigurdsson J, et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol. 2006;124:1711-1718.
5. Löfqvist C, Hansen-Pupp I, Andersson E, et al. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulin like growth factor I. Arch Ophthalmol. 2009;127:622-627.
6. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia: a clinical approach. Med J Aust. 1951;2:48-50.
7. Patz A, Hoeck LE, De La Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia: I. Nursery observations. Am J Ophthalmol. 1952;35:1248-1253.
8. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
9. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10:133-140.
10. Ashton N, Ward B, Serpell G. Effect of oxygen of developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol. 1954;38:397-432.
11. Lutty GA, Chan-Ling T, Phelps DL, et al. Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis. 2006;12:532-580.
12. Fortes Filho JB, Bonomo PP, Maia M, et al. Weight gain measured at 6 weeks after birth as a predictor for severe retinopathy of prematurity: study with 317 very low birth weight preterm babies. Graefes Arch Clin Exp Ophthalmol. 2009;247:831-836.
13. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;21:426-430.
14. Cekmez F, Pirgon O, Tanju IA, et al. Cord plasma concentrations of visfatin, adiponectin and insulin in healthy term neonates: positive correlation with birthweight. Int J Biomed Sci. 2009;5:3.
15. Mazaki-Tovi S, Vaisbuch E, Romero R, et al. Maternal and neonatal circulating visfatin concentrations in patients with pre-eclampsia and a small-for-gestational age neonate. J Matern Fetal Neonatal Med. 2010;23:1119-1128.
16. Langford K, Nicolaides K, Miell JP. Maternal and fetal insulinlike growth factors and their binding proteins in the second and third trimesters of human pregnancy. Hum Reprod. 1998;13:1389-1393.
17. Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol. 1984;102:1130-1134.
18. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684-1694.
19. Davenport ML, Svoboda ME, Koerber KL, et al. Plasma concentrations of insulin-like growth factor II (IGF-II) are not changed by short-term fasting and refeeding. J Clin Endocrinol Metab. 1988;67:1231-1236.
20. American Academy of Pediatrics, Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2006;117:572-576.
21. Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division: evidence that 'physiological hypoxia' is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci. 1995;36:1201-1214.
22. Hellström A, Carlsson B, Niklasson A, et al. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab. 2002;87:3413-3416.
23. Holly J, Perks C. The role of insulin-like growth factor binding proteins. Neuroendocrinology. 2006;83:154-160.
24. Lineham JD, Smith RM, Dahlenburg GW, et al. Circulating insulin-like growth factor I levels in newborn premature and full-term infants followed longitudinally. Early Hum Dev. 1986;13:37-46.
25. Meral C, Cekmez F, Pirgon O, et al. The relationship between serum visfatin, adiponectin, and insulin sensitivity markers in neonates after birth. J Matern Fetal Neonatal Med. 2011;24:166-170.
26. Kaminska A, Kopczynska E, Bronisz A, et al. An evaluation of visfatin levels in obese subjects. Endokrynol Pol. 2010;61:169-173.
27. Kolsgaard ML, Wangensteen T, Brunborg C, et al. Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome. Scand J Clin Lab Invest. 2009;69:858-864.
28. Dedoussis GV, Kapiri A, Samara A, et al. Visfatin: the link between inflammation and childhood obesity. Diabetes Care. 2009;32:e71.
29. Martos-Moreno GA, Kratzsch J, Körner A, et al. Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism [published online ahead of print January 25, 2011]. Int J Obes (Lond).
30. Smith WJ, Underwood LE, Keyes L, Clemmons DR. Use of insulin-like growth factor I (IGF-I) and IGF-binding protein measurements to monitor feeding of premature infants. J Clin Endocrinol Metab. 1997;82:3982-3988.